ZA200201744B - Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins. - Google Patents

Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins. Download PDF

Info

Publication number
ZA200201744B
ZA200201744B ZA200201744A ZA200201744A ZA200201744B ZA 200201744 B ZA200201744 B ZA 200201744B ZA 200201744 A ZA200201744 A ZA 200201744A ZA 200201744 A ZA200201744 A ZA 200201744A ZA 200201744 B ZA200201744 B ZA 200201744B
Authority
ZA
South Africa
Prior art keywords
estramustine phosphate
cancer
sulfoalkyl ether
cyclodextrin
formulation
Prior art date
Application number
ZA200201744A
Other languages
English (en)
Inventor
Lorena Muggetti
Paolo Colombo
Allessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of ZA200201744B publication Critical patent/ZA200201744B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200201744A 1999-09-16 2002-03-01 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins. ZA200201744B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9921958.6A GB9921958D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins

Publications (1)

Publication Number Publication Date
ZA200201744B true ZA200201744B (en) 2004-01-28

Family

ID=10861068

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201744A ZA200201744B (en) 1999-09-16 2002-03-01 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins.

Country Status (19)

Country Link
US (1) US6730664B1 (pl)
EP (1) EP1212041A1 (pl)
JP (1) JP2003509356A (pl)
KR (1) KR20020059401A (pl)
CN (1) CN1374857A (pl)
AU (1) AU777684B2 (pl)
BR (1) BR0014062A (pl)
CA (1) CA2385065A1 (pl)
CZ (1) CZ2002944A3 (pl)
EA (1) EA003936B1 (pl)
GB (1) GB9921958D0 (pl)
HU (1) HUP0300185A3 (pl)
IL (1) IL148408A0 (pl)
MX (1) MXPA02002855A (pl)
NO (1) NO20021270D0 (pl)
PL (1) PL356026A1 (pl)
SK (1) SK3462002A3 (pl)
WO (1) WO2001019339A1 (pl)
ZA (1) ZA200201744B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
NZ592293A (en) * 2005-11-28 2012-10-26 Verrow Pharmaceuticals Inc Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP4598589A1 (en) * 2022-10-05 2025-08-13 Institut Gustave Roussy An oral liquid composition of vinorelbine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523035A (en) * 1976-03-10 1978-08-31 Leo Ab Derivatives of estradiol - 17 - dihydrogen phosphates
JPS59108800A (ja) 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
HUP0300185A3 (en) 2007-02-28
KR20020059401A (ko) 2002-07-12
CN1374857A (zh) 2002-10-16
HUP0300185A2 (en) 2003-05-28
US6730664B1 (en) 2004-05-04
NO20021270L (no) 2002-03-14
NO20021270D0 (no) 2002-03-14
AU6993900A (en) 2001-04-17
EP1212041A1 (en) 2002-06-12
CA2385065A1 (en) 2001-03-22
EA003936B1 (ru) 2003-10-30
CZ2002944A3 (cs) 2002-08-14
JP2003509356A (ja) 2003-03-11
WO2001019339A1 (en) 2001-03-22
MXPA02002855A (es) 2003-07-21
IL148408A0 (en) 2002-09-12
AU777684B2 (en) 2004-10-28
GB9921958D0 (en) 1999-11-17
SK3462002A3 (en) 2002-08-06
PL356026A1 (pl) 2004-05-31
EA200200370A1 (ru) 2002-10-31
BR0014062A (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
EP1214078B1 (en) Formulations for parenteral use of estramustine phosphate and amino acids
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
WO2001010446A2 (en) Formulations for parenteral use of estramustine phosphate and albumin
AU777763B2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
HK1048946A (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
HK1063153A (en) Formulations for parenteral use of estramustine phosphate and albumin